CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Recruiting
257 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Phase 1/2 Recruiting
96 enrolled
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Phase 3 Recruiting
400 enrolled
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Phase 1 Recruiting
50 enrolled
AHEAD-MERIT
Phase 2/3 Recruiting
350 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
PEEL-224
Phase 1/2 Recruiting
59 enrolled
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
Phase NA Recruiting
30 enrolled
New MRI Biomarkers in Head and Neck Cancers
Recruiting
200 enrolled
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2 Recruiting
22 enrolled
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 Recruiting
27 enrolled
LUPARPED
Phase 1/2 Recruiting
25 enrolled
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Phase 1 Recruiting
180 enrolled
OLYMPIA-5
Phase 3 Recruiting
470 enrolled
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
80 enrolled
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Recruiting
300 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
WOLF
Phase 2 Recruiting
87 enrolled
ADAPT-HEM
Phase 1/2 Recruiting
96 enrolled
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase 1 Recruiting
70 enrolled
FIERCE-HN
Phase 3 Recruiting
410 enrolled
GBM AGILE
Phase 2/3 Recruiting
2,250 enrolled
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Phase 2 Recruiting
32 enrolled
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Phase 1/2 Recruiting
56 enrolled
IMPACT-AML
Phase 3 Recruiting
339 enrolled
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Phase NA Recruiting
48 enrolled
TERZO
Phase 3 Recruiting
124 enrolled
U96-CAR-T-Cells For R/R B-ALL
Phase 1 Recruiting
30 enrolled
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
361 enrolled
iMATRIX GLO
Phase 1/2 Recruiting
65 enrolled
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Phase 1 Recruiting
42 enrolled
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
166 enrolled
Lumi-NHL
Phase 1/2 Recruiting
91 enrolled
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 Recruiting
260 enrolled
Study of Out of Specification for Tisagenlecleucel
Phase 3 Recruiting
200 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1 Recruiting
120 enrolled
LINKER-MM1
Phase 1/2 Recruiting
387 enrolled 3 FDA
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Phase 2 Recruiting
52 enrolled
LUTEON
Phase 3 Recruiting
40 enrolled
KNAN2001
Phase 1 Recruiting
15 enrolled
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
100 enrolled
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 Recruiting
115 enrolled
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting
104 enrolled